Senescence in Chronic Kidney Disease

Enrolling by invitation · Phase 2

Conditions studied: Chronic Kidney Disease

In brief

The study goal is to assess the effect of senescent cell clearance on senescence burden, physical ability or frailty, and adipose tissue-derived mesenchymal stem cell (MSC) functionality in patients with chronic kidney disease (CKD).

Key facts

Study ID

NCT02848131

Run by

Mayo Clinic

People needed

30

Starts

2016-07-01

Expected to finish

2027-04-01

Last updated by the study team

2026-05-19

Who can join

Age: 40 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 40-80 years
• Chronic kidney disease estimated glomerular filtration rate (eGFR) 15-45 ml/min/1.73m2
• Diabetes mellitus and taking diabetes medications

You may not qualify if…

• Concomitant glomerulonephritis,
• Nephrotic syndrome,
• Solid organ transplantation,
• Autosomal dominant or recessive polycystic kidney disease,
• Known renovascular disease,
• Pregnancy,
• Active immunosuppression therapy,
• Hemoglobin A1c≥10% at screening,
• History of active substance abuse (including alcohol) within the past 2 years,
• Current alcohol abuse (>3 alcoholic beverages/day or >21 per week),
• Body weight >150 kg or body mass index>50
• Human immunodeficiency virus infection
• Active hepatitis B or C infection
• Tyrosine kinase inhibitor therapy
• Known hypersensitivity or allergy to dasatinib or quercetin
• Inability to give informed consent
• Uncontrolled systemic lupus erythematosus
• Uncontrolled pleural/pericardial effusions or ascites
• New invasive cancer except non-melanoma skin cancers
• Invasive fungal or viral infection
• Inability to tolerate oral medications
• Total bilirubin>2x upper limit of normal
• Subjects taking medications that are sensitive to substrates or substrates with a narrow therapeutic range for CYP3A4, CYP2C8, CYP2C9, or CYP2D6 or strong inhibitors or inducers of CYP3A4 (e.g. cyclosporine, tacrolimus or sirolimus). If antifungals are absolutely necessary from an infectious disease perspective, then they will be allowed only if the levels are therapeutic.
• Subjects on strong inhibitors of CYP3A4.
• Subjects on therapeutic doses of anticoagulants (Warfarin (Coumadin);Rivaroxaban (Xarleto); Apixaban (Eliquis); Dabigatran (Pradaxa, Prazaxa) or Other).

Where it is running

• Mayo Clinic Florida — Jacksonville, Florida, United States
• Mayo Clinic in Rochester — Rochester, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.